Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Shattuck Labs Inc STTK

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40... see more

NDAQ:STTK - Post Discussion

Shattuck Labs Inc > Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs,
View:
Post by whytestocks on Oct 14, 2024 6:15pm

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs,

Just In: $STTK Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities InvestigationNEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional...STTK - Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation
Be the first to comment on this post